Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study

M. Malagola, A. Iurlo, E. Abruzzese, M. Bonifacio, F. Stagno, G. Binotto, M. D’Adda, M. Lunghi, M. Crugnola, M.L. Ferrari, F. Lunghi, F. Castagnetti, G. Rosti, R.M. Lemoli, R. Sancetta, M.R. Coppi, M.T. Corsetti, G. Rege Cambrin, A. Romano, A. De VivoA. Russo Rossi, S. Russo, L. Aprile, M. Bocchia, L. Gandolfi, M. Farina, S. Bernardi, N. Polverelli, A.M. Roccaro, M. Baccarani, D. Russo

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1726-1737
Number of pages12
JournalCancer Medicine
Volume10
Issue number5
DOIs
Publication statusPublished - 2021

Keywords

  • chronic myeloid leukaemia
  • intermittent
  • quality of life
  • tyrosine kinase inhibitor
  • dasatinib
  • imatinib
  • nilotinib
  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
  • protein kinase inhibitor
  • pyrimidine derivative
  • adult
  • aged
  • appendicitis
  • artery disease
  • arthritis
  • Article
  • ascites
  • atrial fibrillation
  • blast cell
  • bronchitis
  • cancer growth
  • cancer patient
  • chill
  • chronic myeloid leukemia
  • conjunctival hemorrhage
  • controlled study
  • data analysis
  • diarrhea
  • drowsiness
  • drug intermittent therapy
  • drug response
  • dyspnea
  • female
  • fever
  • gender
  • geriatric patient
  • hand pain
  • heart failure
  • hip fracture
  • human
  • hypertension
  • hypotension
  • influenza
  • inguinal hernia
  • interim analysis
  • Italy
  • leg edema
  • longitudinal study
  • maintenance therapy
  • major clinical study
  • male
  • molecular response
  • muscle cramp
  • patient monitoring
  • peer group
  • perianal abscess
  • periorbital edema
  • phase 3 clinical trial
  • pneumonia
  • postvitreous detachment
  • probability
  • pruritus
  • randomized controlled trial
  • reverse transcription polymerase chain reaction
  • side effect
  • clinical trial
  • disease exacerbation
  • drug administration
  • middle aged
  • preliminary data
  • sex factor
  • time factor
  • very elderly
  • Aged
  • Aged, 80 and over
  • Dasatinib
  • Disease Progression
  • Drug Administration Schedule
  • Female
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Male
  • Middle Aged
  • Preliminary Data
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Quality of Life
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sex Factors
  • Time Factors

Cite this